{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:50:47Z","timestamp":1765547447665,"version":"3.41.2"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Cystic Fibrosis (CF) is a hereditary condition and can cause permanent respiration problems leading to degraded life quality. The most common variation leading to CF is the F508del variation. CF can cause damage to not just the lungs but also digestive system, pancreas, and other organs. CF decreases the life expectancy of the individuals affected with the constant fear of lung complications. The current methods of treatment include using a combination of drugs to manage the symptoms. The combination of drugs has many side effects and causes damage to other organs like liver, heart or kidneys. In this study, we aim to find a drug that can relieve the symptoms of CF. We began by creating a dataset of potential drug molecules, which was subsequently refined by removing harmful compounds through an ADMET scan. All these compounds were then docked to the mutated Cystic Fibrosis Transmembrane Regulator (CFTR) protein. The compounds with the best docking affinity were Galicaftor and Bamocaftor. A currently approved drug, Ivacaftor was selected as control for the 200 ns Molecular Dynamics (MD) Simulation. The simulation revealed that the CFTR protein remained more stable and compact when complexed with Bamocaftor, when compared to Ivacaftor and Galicaftor. Moreover, the MMPBSA free energy calculations revealed that the free energy of the CFTR-bamocaftor complex is the lowest compared to the other complexes. Our findings reveal the action of bamocaftor on CFTR protein with p.Phe508del variation. However, the absence of in-vivo or in-vitro studies is a limitation, and further experimental validation is necessary to confirm its efficacy and safety.<\/jats:p>","DOI":"10.1371\/journal.pone.0328051","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T17:43:48Z","timestamp":1753292628000},"page":"e0328051","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Understanding the action of bamocaftor as a potential drug candidate against Cystic Fibrosis Transmembrane Regulator protein: A computational approach"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6473-9224","authenticated-orcid":true,"given":"Naisarg","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samrat","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1151-9721","authenticated-orcid":true,"given":"Bala Murali","family":"V M","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishan","family":"Kashyap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Premkumar","family":"Thiruselvam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vino","family":"Sundararajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3392-4168","authenticated-orcid":true,"given":"Sajitha","family":"Lulu Sudhakaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"issue":"2","key":"pone.0328051.ref001","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jcf.2010.12.005","article-title":"An overview of international literature from cystic fibrosis registries. Part 3. Disease incidence, genotype\/phenotype correlation, microbiology, pregnancy, clinical complications, lung transplantation, and miscellanea","volume":"10","author":"D Salvatore","year":"2011","journal-title":"J Cyst Fibros"},{"issue":"1","key":"pone.0328051.ref002","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jcf.2006.05.008","article-title":"A survey of newborn screening for cystic fibrosis in Europe","volume":"6","author":"KW Southern","year":"2007","journal-title":"J Cyst Fibros"},{"issue":"4","key":"pone.0328051.ref003","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1085\/jgp.201711946","article-title":"Structural mechanisms of CFTR function and dysfunction","volume":"150","author":"TC Hwang","year":"2018","journal-title":"The Journal of General Physiology"},{"key":"pone.0328051.ref004","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1146\/annurev.ge.29.120195.004021","article-title":"Cystic fibrosis: genotypic and phenotypic variations","volume":"29","author":"J Zielenski","year":"1995","journal-title":"Annu Rev Genet"},{"issue":"10290","key":"pone.0328051.ref005","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"M Shteinberg","year":"2021","journal-title":"The Lancet"},{"issue":"8","key":"pone.0328051.ref006","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009720","article-title":"Structure and function of the mucus clearance system of the lung","volume":"3","author":"BM Button","year":"2013","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"issue":"12","key":"pone.0328051.ref007","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/ppul.20677","article-title":"Cystic fibrosis in India","volume":"42","author":"SK Kabra","year":"2007","journal-title":"Pediatric Pulmonology"},{"year":"2021","author":"CFF","key":"pone.0328051.ref008"},{"key":"pone.0328051.ref009","article-title":"Real-world disparities and ethical considerations with access to CFTR modulator drugs: Mind the gap!","author":"M Zampoli","year":"2023","journal-title":"Frontiers in Pharmacology"},{"key":"pone.0328051.ref010","article-title":"Therapeutic approaches to CFTR dysfunction: From discovery to drug development","volume":"17","author":"H Li","year":"2018","journal-title":"J Cyst Fibros"},{"key":"pone.0328051.ref011","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine","volume":"10","author":"M Lopes-Pacheco","year":"2020","journal-title":"Front Pharmacol"},{"key":"pone.0328051.ref012","doi-asserted-by":"crossref","first-page":"116120","DOI":"10.1016\/j.ejmech.2023.116120","article-title":"Small molecule modulators of cystic fibrosis transmembrane conductance regulator (CFTR): Structure, classification, and mechanisms","volume":"265","author":"L Cao","year":"2024","journal-title":"European Journal of Medicinal Chemistry"},{"key":"pone.0328051.ref013","doi-asserted-by":"crossref","first-page":"113195","DOI":"10.1016\/j.ejmech.2021.113195","article-title":"Modulators of CFTR. Updates on clinical development and future directions","volume":"213","author":"E Bardin","year":"2021","journal-title":"European Journal of Medicinal Chemistry"},{"key":"pone.0328051.ref014","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.coph.2017.09.016","article-title":"Corrector combination therapies for F508del-CFTR","volume":"34","author":"W Hanrahan","year":"2017","journal-title":"Current Opinion in Pharmacology"},{"issue":"9","key":"pone.0328051.ref015","article-title":"Newly discovered cutting-edge triple combination cystic fibrosis therapy: A systematic review","volume":"14","author":"SN Dawood","year":"2022","journal-title":"Cureus"},{"issue":"1","key":"pone.0328051.ref016","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/cpt.548","article-title":"Can cystic fibrosis patients finally catch a breath with lumacaftor\/ivacaftor?","volume":"101","author":"E Schneider","year":"2016","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"2","key":"pone.0328051.ref017","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1021\/ci800305f","article-title":"OSIRIS, an entirely in-house developed drug discovery informatics system","volume":"49","author":"T Sander","year":"2009","journal-title":"J Chem Inf Model"},{"author":"T Sander","key":"pone.0328051.ref018"},{"issue":"8","key":"pone.0328051.ref019","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1021\/acs.jcim.8b00312","article-title":"Evaluation of AutoDock and AutoDock Vina on the CASF-2013 Benchmark","volume":"58","author":"T Gaillard","year":"2018","journal-title":"Journal of Chemical Information and Modeling"},{"issue":"8","key":"pone.0328051.ref020","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock Vina 1.2.0: New docking methods, expanded force field, and Python bindings","volume":"61","author":"J Eberhardt","year":"2021","journal-title":"Journal of Chemical Information and Modeling"},{"issue":"1","key":"pone.0328051.ref021","doi-asserted-by":"crossref","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: visual molecular dynamics","volume":"14","author":"W Humphrey","year":"1996","journal-title":"J Mol Graph"},{"key":"pone.0328051.ref022","article-title":"DrugBank 6.0: the DrugBank knowledgebase for 2024","volume":"52","author":"C Knox","year":"2023","journal-title":"Nucleic Acids Research"},{"author":"Bank RPD.","key":"pone.0328051.ref023"},{"issue":"6617","key":"pone.0328051.ref024","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1126\/science.ade2216","article-title":"Molecular structures reveal synergistic rescue of \u0394508 CFTR by Trikafta modulators","volume":"378","author":"K Fiedorczuk","year":"2022","journal-title":"Science"},{"issue":"20","key":"pone.0328051.ref025","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1093\/bioinformatics\/btw367","article-title":"AutoSite: an automated approach for pseudo-ligands prediction-from ligand-binding sites identification to predicting key ligand atoms","volume":"32","author":"PA Ravindranath","year":"2016","journal-title":"Bioinformatics"},{"year":"2023","author":"Biovia. Discovery Studio","key":"pone.0328051.ref026"},{"issue":"7","key":"pone.0328051.ref027","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/bioinformatics\/btt055","article-title":"GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit","volume":"29","author":"S Pronk","year":"2013","journal-title":"Bioinformatics"},{"key":"pone.0328051.ref028","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers","author":"MJ Abraham","year":"2015","journal-title":"SoftwareX"},{"issue":"1","key":"pone.0328051.ref029","doi-asserted-by":"crossref","DOI":"10.33011\/livecoms.1.1.5068","article-title":"From proteins to perturbed hamiltonians: A suite of tutorials for the gromacs-2018 molecular simulation package","volume":"1","author":"J Lemkul","year":"2019","journal-title":"Living Journal of Computational Molecular Science"},{"issue":"4","key":"pone.0328051.ref030","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/jcc.21367","article-title":"CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields","volume":"31","author":"K Vanommeslaeghe","year":"2010","journal-title":"J Comput Chem"},{"issue":"1","key":"pone.0328051.ref031","doi-asserted-by":"crossref","DOI":"10.1186\/1758-2946-4-17","article-title":"Avogadro: an advanced semantic chemical editor, visualization, and analysis platform","volume":"4","author":"MD Hanwell","year":"2012","journal-title":"Journal of Cheminformatics"},{"issue":"14","key":"pone.0328051.ref032","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1021\/acs.jcim.3c00860","article-title":"charmm2gmx: An Automated Method to Port the CHARMM Additive Force Field to GROMACS","volume":"63","author":"AF Wacha","year":"2023","journal-title":"J Chem Inf Model"},{"issue":"10","key":"pone.0328051.ref033","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","article-title":"gmx_MMPBSA: A New Tool to Perform End-State Free Energy Calculations with GROMACS","volume":"17","author":"MS Vald\u00e9s-Tresanco","year":"2021","journal-title":"J Chem Theory Comput"},{"issue":"2","key":"pone.0328051.ref034","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1021\/ct100578z","article-title":"PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions","volume":"7","author":"MHM Olsson","year":"2011","journal-title":"J Chem Theory Comput"},{"issue":"8","key":"pone.0328051.ref035","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.bbabio.2006.06.005","article-title":"Factors influencing the energetics of electron and proton transfers in proteins. What can be learned from calculations","volume":"1757","author":"MR Gunner","year":"2006","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"pone.0328051.ref036","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jcf.2023.09.008","article-title":"Standards for the care of people with cystic fibrosis (CF): A timely and accurate diagnosis","volume":"22","author":"C Castellani","year":"2023","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"pone.0328051.ref037","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/biom4020498","article-title":"Decoding F508del misfolding in cystic fibrosis","volume":"4","author":"XR Wang","year":"2014","journal-title":"Biomolecules"},{"issue":"5","key":"pone.0328051.ref038","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/01.GIM.0000139506.11694.7C","article-title":"Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel","volume":"6","author":"MS Watson","year":"2004","journal-title":"Genet Med"},{"issue":"3","key":"pone.0328051.ref039","doi-asserted-by":"crossref","first-page":"2002645","DOI":"10.1183\/13993003.02645-2020","article-title":"Carriers of a single CFTR mutation are asymptomatic: an evolving dogma?","volume":"56","author":"C Martin","year":"2020","journal-title":"Eur Respir J"},{"year":"2023","key":"pone.0328051.ref040"},{"author":"TRIKAFTA\u00ae","key":"pone.0328051.ref041"},{"issue":"10","key":"pone.0328051.ref042","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1039\/C7MD00381A","article-title":"A systematic analysis of atomic protein-ligand interactions in the PDB","volume":"8","author":"R Ferreira de Freitas","year":"2017","journal-title":"Medchemcomm"},{"article-title":"A study to evaluate the safety, tolerability, and efficacy of galicaftor\/navocaftor\/ABBV-119 combination therapy in subjects with cystic fibrosis","year":"2022","author":"D Peckham","key":"pone.0328051.ref043"},{"issue":"17","key":"pone.0328051.ref044","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1807119","article-title":"VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles","volume":"379","author":"JC Davies","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0328051.ref045","doi-asserted-by":"crossref","first-page":"102542","DOI":"10.1016\/j.isci.2021.102542","article-title":"Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulator","volume":"24","author":"O Laselva","year":"2021","journal-title":"iScience"},{"issue":"6","key":"pone.0328051.ref046","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/jmr.2447","article-title":"Drug-drug plasma protein binding interactions of ivacaftor","volume":"28","author":"EK Schneider","year":"2015","journal-title":"J Mol Recognit"},{"issue":"3","key":"pone.0328051.ref047","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1501240","article-title":"Regulation of protein-ligand binding affinity by hydrogen bond pairing","volume":"2","author":"D Chen","year":"2016","journal-title":"Science Advances"},{"key":"pone.0328051.ref048","first-page":"193","article-title":"Principal Component Analysis: A Method for Determining the Essential Dynamics of Proteins","author":"CC David","year":"2013","journal-title":"Protein Dynamics"},{"issue":"5","key":"pone.0328051.ref049","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","article-title":"The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities","volume":"10","author":"S Genheden","year":"2015","journal-title":"Expert Opin Drug Discov"},{"issue":"2","key":"pone.0328051.ref050","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1017\/S0033583513000024","article-title":"Protonation and pK changes in protein-ligand binding","volume":"46","author":"AV Onufriev","year":"2013","journal-title":"Q Rev Biophys"},{"key":"pone.0328051.ref051","doi-asserted-by":"crossref","first-page":"22523","DOI":"10.1038\/srep22523","article-title":"Mimicking titration experiments with MD simulations: A protocol for the investigation of pH-dependent effects on proteins","volume":"6","author":"E Socher","year":"2016","journal-title":"Sci Rep"},{"issue":"17","key":"pone.0328051.ref052","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445\u2013Tezacaftor\u2013Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles","volume":"379","author":"D Keating","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"pone.0328051.ref053","article-title":"Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment","volume":"11","author":"CA Shaughnessy","year":"2021","journal-title":"Scientific Reports"},{"issue":"6","key":"pone.0328051.ref054","doi-asserted-by":"crossref","first-page":"2002774","DOI":"10.1183\/13993003.02774-2020","article-title":"Rescue of multiple class II CFTR mutations by elexacaftor tezacaftor ivacaftor mediated in part by the dual activities of Elexacaftor as both corrector and potentiator","volume":"57","author":"O Laselva","year":"2020","journal-title":"European Respiratory Journal"},{"issue":"2","key":"pone.0328051.ref055","article-title":"Mental status changes during elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"21","author":"S Heo","year":"2021","journal-title":"Journal of Cystic Fibrosis"},{"issue":"6446","key":"pone.0328051.ref056","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1126\/science.aaw7611","article-title":"Structural identification of a hotspot on CFTR for potentiation","volume":"364","author":"F Liu","year":"2019","journal-title":"Science"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0328051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T17:44:02Z","timestamp":1753292642000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0328051"}},"subtitle":[],"editor":[{"given":"Jordi","family":"Vill\u00e0-Freixa","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":56,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0328051","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2025,7,23]]}}}